Special Issue "Rejection and Tolerance in HSCT and SOT"
Deadline for manuscript submissions: 31 October 2021.
Interests: hematopoietic stem cell transplantation; graft manipulation; graft failure; graft-versus-host disease; immunotherapy; hemophagocytic lymphohistiocytosis; fecal microbiota transplantation
Special Issues and Collections in MDPI journals
2. Division of Hematology, Oncology, and Stem Cell Transplantation, Helsinki University Hospital, Helsinki, Finland
Interests: pediatric hematology; hematopoietic stem cell transplantation; immunodeficiencies
The number of hematopoietic stem cell transplantations (HSCT) and solid organ transplantations (SOT) is constantly increasing. Better understanding the complex immunology involved with transplantation, together with enhanced supportive care, has reduced toxicity and made it possible to widen the indications for transplantation therapy and to treat more fragile patients. However, transplantation techniques still bear a significant risk of toxicity, which can be life threatening. Most of these toxic complications relate directly to alloreactivity or medications used to prevent and control alloreactivity.
In HSCT, the use of alternative donors (i.e., mismatched unrelated donors, haploidentical relatives, and unrelated cord blood units) has made it possible to transplant patients lacking a matched sibling or unrelated donor. Since an increasing number of HSCT are done with alternative donors, the prevention and control of bidirectional alloreactivity, resulting in graft rejection and failure (both primary or secondary) and graft-versus-host disease (GVHD), is becoming more challenging.
Although HSCT patients are weaned off immunosuppressive medication, patients that receive SOT require lifelong immunosuppression, causing long-term toxicity. Moreover, all immunosuppressive schemes are suboptimal in preventing chronic rejection. Accordingly, several research groups are pursuing different strategies to induce tolerance of the transplanted organ, abolishing chronic rejection and allowing for cessation of immunosuppressive medication. These approaches vary according to cellular products and the combination of drugs employed.
This Special Issue, “Rejection and Tolerance in HSCT and SOT”, welcomes original research and review articles in this rapidly developing field, with a focus on preclinical and clinical data on graft failure and GVHD after HSCT, as well as cellular and humoral graft rejection after SOT. Viewpoint and perspective articles, as well as protocols of tolerance induction for SOT, are also warmly welcome.
Dr. Pietro Merli
Dr. Samppa J. Ryhänen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- hematopoietic stem cell transplantation
- solid organ transplantation
- graft-vs-host disease
- graft rejection
- immunological tolerance
- graft manipulation